Literature DB >> 36138411

Drug classification for patients with comorbidities.

Farid Belialov1.   

Abstract

Entities:  

Keywords:  Cirrhosis; Comorbidity; Coronary artery disease; Drug classification; Mental disorder; Multimorbidity

Year:  2022        PMID： 36138411     DOI： 10.1186/s40545-022-00453-9

Source DB:  PubMed          Journal:  J Pharm Policy Pract        ISSN： 2052-3211


× No keyword cloud information.
  19 in total

Review 1.  Statin Use and Risk of Cirrhosis and Related Complications in Patients With Chronic Liver Diseases: A Systematic Review and Meta-analysis.

Authors:  Rebecca G Kim; Rohit Loomba; Larry J Prokop; Siddharth Singh
Journal:  Clin Gastroenterol Hepatol       Date:  2017-05-04       Impact factor: 11.382

2.  2021 European Heart Rhythm Association Practical Guide on the Use of Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation.

Authors:  Jan Steffel; Ronan Collins; Matthias Antz; Pieter Cornu; Lien Desteghe; Karl Georg Haeusler; Jonas Oldgren; Holger Reinecke; Vanessa Roldan-Schilling; Nigel Rowell; Peter Sinnaeve; Thomas Vanassche; Tatjana Potpara; A John Camm; Hein Heidbüchel; Gregory Y H Lip; Thomas Deneke; Nikolaos Dagres; Giuseppe Boriani; Tze-Fan Chao; Eue-Keun Choi; Mellanie True Hills; Itamar de Souza Santos; Deirdre A Lane; Dan Atar; Boyoung Joung; Oana Maria Cole; Mark Field
Journal:  Europace       Date:  2021-04-25       Impact factor: 5.214

3.  Cardiovascular safety of one-year escitalopram therapy in clinically nondepressed patients with acute coronary syndrome: results from the DEpression in patients with Coronary ARtery Disease (DECARD) trial.

Authors:  Jamal A Hanash; Baiba H Hansen; Jørgen F Hansen; Olav W Nielsen; Alice Rasmussen; Morten Birket-Smith
Journal:  J Cardiovasc Pharmacol       Date:  2012-10       Impact factor: 3.105

4.  Depression treatment after myocardial infarction and long-term risk of subsequent cardiovascular events and mortality: a randomized controlled trial.

Authors:  Marij Zuidersma; Henk Jan Conradi; Joost P van Melle; Johan Ormel; Peter de Jonge
Journal:  J Psychosom Res       Date:  2012-09-23       Impact factor: 3.006

5.  Effect of hepatic impairment on the pharmacokinetics and pharmacodynamics of a single dose of rivaroxaban, an oral, direct Factor Xa inhibitor.

Authors:  Dagmar Kubitza; Angelika Roth; Michael Becka; Abir Alatrach; Atef Halabi; Holger Hinrichsen; Wolfgang Mueck
Journal:  Br J Clin Pharmacol       Date:  2013-07       Impact factor: 4.335

6.  Determinants and escitalopram treatment effects on suicidal ideation in patients with acute coronary syndrome: Findings from the K-DEPACS and EsDEPACS studies.

Authors:  Jae-Min Kim; Hee-Ju Kang; Kyung-Yeol Bae; Sung-Wan Kim; Il-Seon Shin; Young Joon Hong; Youngkeun Ahn; Myung Ho Jeong; Hyuno Kang; Jin-Sang Yoon
Journal:  Int J Cardiol       Date:  2016-06-14       Impact factor: 4.164

7.  The EURO-FORTA (Fit fOR The Aged) List: International Consensus Validation of a Clinical Tool for Improved Drug Treatment in Older People.

Authors:  Farhad Pazan; Christel Weiss; Martin Wehling
Journal:  Drugs Aging       Date:  2018-01       Impact factor: 3.923

Review 8.  Secondary prophylaxis of variceal bleeding for cirrhotic patients: a multiple-treatments meta-analysis.

Authors:  Ke-Qing Shi; Wen-Yue Liu; Zhen-Zhen Pan; Xiang-Feng Ling; Shao-Long Chen; Yong-Ping Chen; Yu-Chen Fan; Ming-Hua Zheng
Journal:  Eur J Clin Invest       Date:  2013-08       Impact factor: 4.686

9.  Treatment of post-myocardial infarction depressive disorder: a randomized, placebo-controlled trial with mirtazapine.

Authors:  Adriaan Honig; Astrid M G Kuyper; Aart H Schene; Joost P van Melle; Peter de Jonge; Dorien M Tulner; Annique Schins; Harry J G M Crijns; Petra M J C Kuijpers; Helen Vossen; Richel Lousberg; Johan Ormel
Journal:  Psychosom Med       Date:  2007-09-10       Impact factor: 4.312

10.  Comprehensive evaluation of effects and safety of statin on the progression of liver cirrhosis: a systematic review and meta-analysis.

Authors:  Yue Gu; Xueqin Yang; Hang Liang; Deli Li
Journal:  BMC Gastroenterol       Date:  2019-12-30       Impact factor: 3.067
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.